NURIX THERAPEUTICS INC

Nurix Therapeutics reports Q2 2026 earnings miss, but highlights Roche partnership and protein‑level modulation pipeline, signaling continued focus on innovative treatments.

Nurix Therapeutics reported strong Q2 financial results, exceeding market expectations, but received mixed analyst opinions with some firms lowering their stock price targets while others initiated coverage with a ‘Buy’ rating.

Nurix Therapeutics, a pioneering biopharmaceutical company, is developing innovative treatments for underserved patients by controlling protein levels within cells, offering new possibilities for disease treatment.

Nurix Therapeutics, a biopharmaceutical company, is pioneering a new approach to disease treatment by controlling protein levels within cells, positioning it as a key player in the healthcare industry.